Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

9:40pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Arrowhead Pharmaceuticals files for mixed shelf of up to $200 mln - SEC filing
Saturday, 29 Oct 2016 

Arrowhead Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing.  Full Article

Arrowhead Pharma files for sale of aggregate of 3 mln shares of co's common stock by selling shareholder Amgen
Saturday, 29 Oct 2016 

Amgen Inc : Arrowhead Pharmaceuticals Inc - Files for sale of aggregate of 3.0 million shares of co's common stock by selling shareholder Amgen Inc - SEC filing .Arrowhead Pharmaceuticals Inc - Co will not receive any proceeds from sale by selling stockholders of shares.  Full Article

Arrowhead Pharmaceuticals announces sale of about 7.6 mln shares
Saturday, 3 Sep 2016 

Arrowhead Pharmaceuticals Inc :Sale of an aggregate of 7.6 million shares of common stock, $0.001 par value per share by selling stockholders - sec filing.  Full Article

Arrowhead Pharma qtrly loss $0.32 per share
Wednesday, 10 Aug 2016 

: Arrowhead reports fiscal 2016 third quarter results .Arrowhead pharmaceuticals inc qtrly basic and diluted loss per share $0.32.  Full Article

Arrowhead Pharmaceuticals reports Q2 loss per share $0.35
Wednesday, 11 May 2016 

Arrowhead Pharmaceuticals Inc : Q2 loss per share $0.35 .Q2 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Arrowhead Research Corp changes name to Arrowhead Pharmaceuticals
Thursday, 7 Apr 2016 

Arrowhead Research Corp:Has changed its corporate name to Arrowhead Pharmaceuticals Inc.  Full Article

Arrowhead Research Corp's ARC-AAT Granted EMA Orphan Drug Designation
Tuesday, 19 Jan 2016 

Arrowhead Research Corp:Says arrowhead's arc-aat granted ema orphan drug designation.  Full Article

BRIEF-Arrowhead Qtrly loss per share $0.07

* Qtrly revenue $9.3 million versus $39,583 Source text for Eikon: Further company coverage: